Takeda Pharm Stock Price, News & Analysis

Takeda proposes new candidates for independent external directors at its upcoming shareholders' meeting on June 29, 2022. The candidates, Kimberly A. Reed and John Maraganore, will replace retiring directors Toshiyuki Shiga and Shiro Kuniya. Additionally, Masami Iijima is nominated as the new chair of the Board Meetings, succeeding Masahiro Sakane. This move aims to enhance governance and diversity within the board. All current members will also be proposed for re-election.

Takeda has received approval from Japan's Ministry of Health, Labour and Welfare for TAKHZYRO (lanadelumab) subcutaneous injection in adults and pediatric patients aged 12 and older for preventing attacks of hereditary angioedema (HAE). This decision is primarily based on results from the global Phase 3 HELP Study and a Japan-specific Phase 3 trial, where 41.7% of patients did not experience attacks over 26 weeks. The drug is already approved in over 50 countries and aims to enhance treatment options for the HAE patient community.

Takeda presented interim real-world data from the Phase 4 EMPOWER study, showing significant improvements in Hereditary Angioedema (HAE) treatment outcomes with TAKHZYRO (lanadelumab). New users experienced an average 83% reduction in monthly attack rates, while established users reported enhanced treatment satisfaction. Key metrics included improvements in the Angioedema Quality of Life Questionnaire and a notable percentage of users extending treatment intervals from every 2 weeks to 4 weeks. Full data is expected in 2024.

Takeda has announced promising six-month interim results from the INSPIRE study, which evaluated the effectiveness of Alofisel (darvadstrocel) in patients with complex Crohn’s perianal fistulas. Clinical remission was observed in 65% of participants, with a clinical response rate of 73% for the All Treated group. The study has enrolled 230 patients as of September 2021. While adverse events were noted in 20% of participants, no serious incidents such as deaths or ectopic tissue formation were reported. These findings align with previous Phase 3 study results, supporting Alofisel's potential as a viable treatment option.

Takeda reported strong Q3 FY2021 results, achieving a +11% year-to-date revenue growth, amounting to 2,695.7 billion yen ($23.4B). The operating profit surged by +28.9% to 462.5 billion yen ($4.0B), with an underlying core operating profit margin of 29.4%. Their 14 global brands accounted for 42% of total core revenue, reflecting a +12% underlying growth. Takeda also upgraded its FY2021 financial forecasts, expecting a free cash flow between 700 billion yen and 800 billion yen.

VONVENDI ([von Willebrand Factor (Recombinant)]) has received FDA approval for routine prophylaxis to reduce bleeding episodes in adults with severe Type 3 von Willebrand disease (VWD) on on-demand therapy. This marks it as the first treatment specifically for this purpose. VWD affects up to 3 million people in the U.S., impacting blood clotting due to a deficiency or dysfunction of von Willebrand factor. Clinical studies showed a 54.7% reduction in annualized bleeding rates. The approval reflects Takeda's commitment to improving care for individuals with VWD.

Takeda Pharmaceutical Company announced its growth strategy and revenue potential at the J.P. Morgan Healthcare Conference. The company is optimistic about generating incremental revenue of JPY 500 billion (approximately $4.5 billion) by FY2025, supported by 14 global brands projected to grow by 14-16%. Takeda's pipeline includes 40 clinical-stage therapies, targeting oncology and rare diseases, aiming for significant regulatory approvals. The company is also committed to maintaining strong cash flow and reducing debt.